Myeloma bone disease: Pathogenetic mechanisms and clinical assessment

Mundy, 1974, Evidence for the secretion of an osteoclast stimulating factor in myeloma, N Engl J Med, 291, 1041, 10.1056/NEJM197411142912001

Terpos, 2003, New insights into the pathophysiology and management of bone disease in multiple myeloma, Br J Haematol, 123, 758, 10.1046/j.1365-2141.2003.04712.x

Standal, 2002, Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells, Blood, 100, 3002, 10.1182/blood-2002-04-1190

Calvani, 2005, Functional osteoclast-like transformation of cultured human myeloma cell lines, Br J Haematol, 130, 926, 10.1111/j.1365-2141.2005.05710.x

Silvestris, 2004, Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells, Br J Haematol, 126, 475, 10.1111/j.1365-2141.2004.05084.x

Tian, 2003, The role of the Wnt-signaling antagonist Dkk1 in the development of osteolytic lesions in multiple myeloma, N Engl J Med, 349, 2483, 10.1056/NEJMoa030847

Giuliani, 2005, Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation, Blood, 106, 2472, 10.1182/blood-2004-12-4986

Oshima, 2005, Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2, Blood, 106, 3160, 10.1182/blood-2004-12-4940

Hjertner, 1999, Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease, Blood, 94, 3883, 10.1182/blood.V94.11.3883

Terpos, 2005, The role of markers of bone remodeling in multiple myeloma, Blood Rev, 19, 125, 10.1016/j.blre.2004.06.001

Abe, 2002, Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma, Blood, 100, 2195, 10.1182/blood.V100.6.2195

Terpos, 2003, Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma, Br J Haematol, 123, 106, 10.1046/j.1365-2141.2003.04561.x

Terpos, 2005, Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma, Leuk Lymphoma, 46, 1699, 10.1080/10428190500175049

Terpos, 2003, Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index, Blood, 102, 1064, 10.1182/blood-2003-02-0380

Berenson, 2002, Advances in the biology and treatment of myeloma bone disease, Semin Oncol, 29, 11, 10.1053/sonc.2002.34071

Croucher, 2003, Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival, J Bone Miner Res, 18, 482, 10.1359/jbmr.2003.18.3.482

Berenson, 2002, American Society of Clinical Oncology Bisphosphonates Expert Panel. American Society of Clinical Oncology Clinical Practice Guidelines: the role of bisphosphonates in multiple myeloma, J Clin Oncol, 20, 3719, 10.1200/JCO.2002.06.037

Sordillo, 2003, RANK-Fc: a therapeutic antagonist for RANK-L in myeloma, Cancer, 97, 802, 10.1002/cncr.11134

Body, 2003, A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases, Cancer, 97, 887, 10.1002/cncr.11138

Nilsson, 1999, Cells capable of bone production engraft from whole bone marrow transplants in nonablated mice, J Exp Med, 189, 729, 10.1084/jem.189.4.729

Bianco, 2001, Bone marrow stromal stem cells: nature, biology, and potential applications, Stem Cells, 19, 180, 10.1634/stemcells.19-3-180